Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.99 +0.58%

+$0.04 today

Market cap
$3.10B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.76M

Average 1.66M

XERS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Xeris Biopharma Holdings, Inc.NASDAQ: XERS

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 170.52M shares rose 11.9% year over year, in line with the +11.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 2.7% from the prior quarter. Over 3 fiscal years it compounded at +5.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +11.9% toward the trailing-twelve-month pace of +11.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
170.52M+2.7% QoQ
Last fiscal yearDec 2025
160.43M+9.3% YoY
LTMMar 2026
167.52M+11.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.9%——
1 year+9.3%——
3-year CAGR+5.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
160.43M USD
Year-over-year change
+9.3%
4-year CAGR
+19.4%

Weighted Avg Shares vs competitors

How XERS compares with its peers on the latest reported figures

  • XERS's LTM Mar 2026 weighted avg shares of 167.52M shares is the 2nd highest of the 9 companies compared; the peer median is 53.64M shares.
  • Its year-over-year change of +11.9% is the 4th highest of 9, against a peer median of +9.1%.
  • Over three fiscal years its annual growth of +5.8% compares with a peer median of +4.6%.
XERS Competitors Peer median
Weighted Avg Shares for XERS and competitors
Company Period LTM YoY 3-year CAGR
MNKDMannKind CorporationLTM Mar 2026306.42M +8.4%+5.9%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026167.52M +11.9%+5.8%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026104.26M +0.4%-0.9%
ASNDAscendis Pharma A/SLTM Sep 202663.29M +4.9%+2.6%
GHRSGH Research PLCLTM Mar 202662.03M +15.9%+5.5%
SEPNSepterna, Inc.LTM Sep 202645.24M +9.8%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 202644.83M +33.4%+4.6%
ETONEton Pharmaceuticals, Inc.LTM Mar 202626.99M +3.1%+2.3%
SPRBSpruce Biosciences, Inc.LTM Mar 2026827.01K +51.8%+7.8%
Peer median (excluding XERS) 53.64M+9.1%+4.6%

Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.59M110.25M163.91M203.07M291.85M
Cost of Revenue13.32M22.63M28.65M36.83M53.41M
Gross Profit36.27M87.61M135.27M166.24M238.43M
Gross Margin73.1%79.5%82.5%81.9%81.7%
Research & Development25.16M20.97M22.34M25.56M31.17M
Selling, General & Admin125.72M137.75M146.1M163.48M182.37M
Operating Expenses151.43M169.55M179.28M199.88M213.54M
Depreciation & Amortization1.88M12.67M13.16M12.63M12.16M
EBITDA(113.67M)(69.31M)(23.74M)(13.99M)12.71M
EBITDA Margin-229.2%-62.9%-14.5%-6.9%4.4%
Operating Income(115.16M)(81.94M)(44.01M)(33.65M)24.9M
Operating Margin-232.2%-74.3%-26.8%-16.6%8.5%
Interest Income313K2.58M4.75M5.32M4.74M
Interest Expense7.18M14.1M26.61M33.18M29.08M
Other Income / Expenses(7.57M)(14.14M)(19.49M)(23.46M)(24.34M)
Income Before Tax(122.73M)(96.08M)(63.5M)(57.1M)554K
Pre-Tax Margin-247.5%-87.2%-38.7%-28.1%0.2%
Income Tax Expense0(1.42M)(1.25M)(2.27M)0
Net Income(122.73M)(94.66M)(62.26M)(54.84M)554K
Net Margin-247.5%-85.9%-38.0%-27.0%0.2%
EPS (Basic)(1.55)(0.70)(0.45)(0.37)0.00
EPS (Diluted)(1.55)(0.70)(0.45)(0.37)0.00
Weighted Avg Shares79.03M135.63M137.67M146.77M160.43M
Weighted Avg Shares (Diluted)79.03M135.63M137.67M146.77M172.74M

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Intrinsic Alpha fair value

Locked

Current Price

$16.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.